We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Trial Hiccups: FDA Panel Nixes Two Indications for Low-Sodium Drug
Trial Hiccups: FDA Panel Nixes Two Indications for Low-Sodium Drug
September 26, 2012
The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 8–0 against recommending approval of Cornerstone Therapeutics’ lixivaptan to treat hypervolemic hyponatremia associated with heart failure, citing poor trial results and dissatisfaction with use of a surrogate endpoint.